Kyoto University-Backed Startup RadioNano Secures Funding for Cancer Drug Development

Overview of the Funding

RadioNano Therapeutics, Inc., a company engaged in the research and development of inorganic nanoparticle formulations for Boron Neutron Capture Therapy (BNCT), has announced the completion of the first close of its Series B funding round. The financing was executed through a third-party allotment of shares, with Mitsui Mining and Smelting Co., Ltd. and Kyoto University Innovation Capital Co., Ltd. acting as underwriters. The specific amount raised has not been disclosed.

About RadioNano Therapeutics

RadioNano Therapeutics is a startup originating from Kyoto University, operating under the mission to "contribute to the health and future of cancer patients and their families through science-driven R&D of novel radiation therapies." Building upon research outcomes from Kyoto University, the company is advancing the R&D of "RN-501," a novel formulation utilizing inorganic nanoparticles rich in boron. The company's high technological capabilities have garnered widespread recognition, including selection in Forbes JAPAN's "100 Japanese Startups to Watch in 2026" and winning the Grand Prix at the 22nd Innovation R&D Grant by The Ikeda Shauku Bank, Ltd.

Purpose of Funding and Future Outlook

Proceeds from this funding round will be allocated toward conducting Phase I/IIa clinical trials for its lead pipeline candidate, "RN-501," establishing a GMP manufacturing and supply framework for investigational drugs, and strengthening the company's overall development structure. "RN-501" leverages nanotechnology to concentrate the drug within cancer tissues, aiming to reduce side effects and expand the range of applicable cancer types. Moving forward, the company plans to evaluate human safety and tolerability through clinical trials while continuing fundraising efforts toward the second close of its Series B round.